No Data
Jiangsu Lianhuan Pharmaceutical (600513.SH): Methanesulfonic acid phenotolamine injection has passed the consistency evaluation of generic drugs.
On March 28, Glonghui reported that Jiangsu Lianhuan Pharmaceutical (600513.SH) announced that it has recently received the drug supplementary application approval notice issued by the National Medical Products Administration for methoxamine injection, and the company's methoxamine injection has passed the consistency evaluation of generic drug quality and efficacy. Methoxamine injection is an α-adrenergic receptor blocker. It is primarily used for the diagnosis of pheochromocytoma and the treatment of hypertension episodes caused by it, including hypertension occurring during surgical resection, and may also assist in diagnosing pheochromocytoma based on the reaction of blood pressure to this product; treating left ventricular failure; and treating norepinephrine.
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Jiangsu Lianhuan Pharmaceutical Nixes Up to 300-Million-Yuan Share Issuance
Jiangsu Lianhuan Pharmaceutical: After nearly 0.3 billion failed placement, plans to borrow 0.2 billion from Banks for Innovative Drugs project "waiting for rice to cook" | Quick read announcement.
① Following the termination of the fundraising plan through the issuance of Convertible Bonds last year, Jiangsu Lianhuan Pharmaceutical has announced the termination of the plan to raise funds by issuing Stocks to specific targets through a simplified procedure. ② In order to develop Innovative Drugs projects, Jiangsu Lianhuan Pharmaceutical intends to apply for a research and development loan from the Jiangsu branch of the National Development Bank, with a credit amount of 0.24 billion yuan.
Jiangsu Lianhuan Pharmaceutical (600513.SH): Terminated the issuance of Stocks to specific targets for the 2024 fiscal year through a simplified procedure.
On February 24, Gelonghui reported that Jiangsu Lianhuan Pharmaceutical (600513.SH) announced that since the company announced the issuance of Stocks to specific targets through a simplified procedure for the year 2024, the company's Board of Directors, management, and intermediary organizations have been actively promoting various tasks. Considering the current market situation, along with the company's actual situation and development plan as well as many other factors, in order to protect the interests of the company and all Shareholders, after thorough communication and careful analysis with relevant parties, the decision was made to terminate the related matters concerning the issuance of Stocks to specific targets through a simplified procedure for the year 2024.
Lianhuan Pharma's Hypertension Drug Gets Registration Certificate
Why Jiangsu Lianhuan Pharmaceutical's (SHSE:600513) Shaky Earnings Are Just The Beginning Of Its Problems
